UNSPSC 51271607: Prilocaine

This classification denotes an anesthetic agent with the molecular formula C13H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 046O35D44R, chemically known as propanamide, n-(2-methylphenyl)-2-(propylamino)-, (s)- but generally known as prilocaine, which bears US NIH Compound Identifier 4906. European Medicines Agency schedules Prilocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10041MIG. The term PRILOCAINE is an International Non-Proprietary Name.

UNSPSC 51271607 Prilocaine, a Commodity code, encompasses local anesthetic pharmaceutical products being procured through state and local cooperative purchasing vehicles for distribution across government health facilities. State and local governments buy prilocaine and related local anesthetics primarily through multi-state pharmaceutical cooperative purchasing agreements rather than direct procurement, enabling bulk pricing negotiations across jurisdictions and authorized wholesaler networks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represents the primary issuing mechanism for this commodity class, with participating members including state health departments, local government facilities, and subordinate purchasing entities across multiple states including Oregon. Vendors must be pharmaceutical manufacturers certified under current Good Manufacturing Practices (cGMP) and compliant with the Drug Supply Chain Security Act (DSCSA), maintaining contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC) and capable of delivering products with National Drug Codes, SKUs, and UPCs through electronic data interchange systems.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (RFP S1070000015802) for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, and contract effectiveness date of July 1, 2026. Evaluation criteria emphasize price competitiveness (75 percent weight), with secondary consideration given to fixed pricing structure (10 percent), compliance with administrative fee format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain comprehensive insurance including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and all products must carry expiration dates at least one year from manufacture with a minimum six-month shelf life. The contract structure provides for two-year terms with optional extensions at MMCAP's discretion, with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.